Evidence map›Paper›PMID 28143431›Full record

Observational studyBMC cancer2017

Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort.

Robert A Vierkant, Amy C Degnim, Derek C Radisky, Daniel W Visscher, Ethan P Heinzen, Ryan D Frank, Stacey J Winham, Marlene H Frost, Christopher G Scott, Matthew R Jensen and 6 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Robert A VierkantDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Amy C DegnimDepartment of Subspecialty General Surgery, Mayo Clinic, Rochester, MN, USA.
Derek C RadiskyDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
Daniel W VisscherDepartment of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA.
Ethan P HeinzenDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Ryan D FrankDepartment of Health Sciences Research, Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL, USA.
Stacey J WinhamDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Marlene H FrostDepartment of Medical Oncology, Division of the Women's Cancer Program, Mayo Clinic, Rochester, MN, USA.
Christopher G ScottDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Matthew R JensenDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Karthik GhoshDepartment of General Internal Medicine, Division of the Breast Diagnostic Clinic, Mayo Clinic, Rochester, MN, USA.
Armando ManducaDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.
Kathleen R BrandtDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Dana H WhaleyDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Lynn C HartmannDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Celine M VachonDepartment of Health Sciences Research, Division of Epidemiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Vachon.Celine@mayo.edu.
Mayo Clinic in Florida · USMayo Clinic in Arizona · USMayo Clinic · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
Molecular Discriminators in Benign Breast Tissue for Future Risk of ER positive aR01CA187112 · NCI · MAYO CLINIC ROCHESTER · PI DEGNIM, AMY C · 2014 to 2018
$2.9M
Identifying high risk mammographic features in women with benign breast diseR21CA186734 · NCI · MAYO CLINIC ROCHESTER · PI VACHON, CELINE M · 2014 to 2015
$401k
NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA187112NCI NIH HHS R21 CA186734
6 · The paper itself

Abstract

backgroundAtypical hyperplasia (AH) and mammographic breast density (MBD) are established risk factors for breast cancer (BC), but their joint contributions are not well understood. We examine associations of MBD and BC by histologic impression, including AH, in a subcohort of women from the Mayo Clinic Benign Breast Disease Cohort.

methodsWomen with a diagnosis of BBD and mammogram between 1985 and 2001 were eligible. Histologic impression was assessed via pathology review and coded as non-proliferative disease (NP), proliferative disease without atypia (PDWA) and AH. MBD was assessed clinically using parenchymal pattern (PP) or BI-RADS criteria and categorized as low, moderate or high. Percent density (PD) was also available for a subset of women. BC and clinical information were obtained by questionnaires, medical records and the Mayo Clinic Tumor Registry. Women were followed from date of benign biopsy to BC, death or last contact. Standardized incidence ratios (SIRs) compared the observed number of BCs to expected counts. Cox regression estimated multivariate-adjusted MBD hazard ratios.

resultsOf the 6271 women included in the study, 1132 (18.0%) had low MBD, 2921 (46.6%) had moderate MBD, and 2218 (35.4%) had high MBD. A total of 3532 women (56.3%) had NP, 2269 (36.2%) had PDWA and 470 (7.5%) had AH. Over a median follow-up of 14.3 years, 528 BCs were observed. The association of MBD and BC risk differed by histologic impression (p-interaction = 0.03), such that there was a strong MBD and BC association among NP (p < 0.001) but non-significant associations for PDWA (p = 0.27) and AH (p = 0.96). MBD and BC associations for AH women were not significant within subsets defined by type of MBD measure (PP vs. BI-RADS), age at biopsy, number of foci of AH, type of AH (lobular vs. ductal) and body mass index, and after adjustment for potential confounding variables. Women with atypia who also had high PD (>50%) demonstrated marginal evidence of increased BC risk (SIR 4.98), but results were not statistically significant.

conclusionWe found no evidence of an association between MBD and subsequent BC risk in women with AH.

Indexed as

BiopsyBreastBreast DensityBreast NeoplasmsCohort StudiesFemaleHumansHyperplasiaMammographyMiddle AgedPrecancerous ConditionsRisk AssessmentRisk FactorsAtypical hyperplasiaBreast cancer riskMammographic breast density

Identifiers

PMID28143431
PMCPMC5282712
OpenAlexW2581294266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.